Use of MRI for Assessing Stomach Relaxation in Response to a Meal

Dynamic MRI - A Novel Approach for Measuring Gastric Accommodation

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00275743

Enrollment

Registered

2006-01-12

Start date

2005-10-31

Completion date

2008-12-31

Last updated

2009-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspepsia, Healthy Volunteers

Brief summary

This study is being done to test new way of measuring the relaxation of the stomach after a meal (called gastric accommodation) by using a MRI scan. This new test will be compared with the standard test of measuring stomach relaxation that uses radioactive tracers. These tests will be compared in healthy volunteers and people with upper abdominal symptoms (known as dyspepsia).

Interventions

PROCEDUREMRI

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

for Dyspeptic patients (30 required) * One or more of eight postprandial dyspeptic symptoms i.e. fullness, bloating, epigastric discomfort, early satiety, nausea, vomiting, belching, pain for a minimum of 3 months, OR * Patients fulfilling the ROME-II criteria for functional dyspepsia, * AND no symptom improvement after standard dose PPI treatment, * AND normal upper gastrointestinal endoscopy within six months prior to the study Inclusion Criteria for Healthy Controls (20 required) • Absence of current abdominal symptoms or depression

Exclusion criteria

for all Participants * Known structural upper GI disorder (e.g. peptic ulcer disease, esophagitis, malignancy); * Abdominal surgery other than appendectomy, cholecystectomy, hysterectomy, tubal ligation, or inguinal hernia repair; * Medications that may alter gastrointestinal motility, e.g., serotoninergic agents, alpha adrenergic agonists, calcium channel or beta blockers; stable dose of thyroxine will be permitted; * Pregnant or breast-feeding females; * Known claustrophobia; * Any metal objects in the body (e.g. metal implants, pacemaker, AICD)

Design outcomes

Primary

Measure	Time frame
Gastric Volume (fasting and postprandial)	—
Antral Contractility	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026